Atlas Trials

Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

Clinical trial NCT04888611 · UNKNOWN

Trial details

NCT number
NCT04888611
Sponsor
Huashan Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Glioblastoma
Start date
2021-10-26
Primary completion
2023-05-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.